BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» Trio of IPOs seek up to $259 million, extending a strong fourth quarter start
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Trio of IPOs seek up to $259 million, extending a strong fourth quarter start
Oct. 17, 2017
By
Michael Fitzhugh
No Comments
Just weeks after the close of a flush third quarter for biotech fundraising, three more drug developers – Apellis Pharmaceuticals Inc., Inflarx NV and Genprex Inc. – are making the leap into the public market with IPOs, all on Nasdaq.
BioWorld